InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Tuesday, 10/13/2020 10:45:30 PM

Tuesday, October 13, 2020 10:45:30 PM

Post# of 7747
Just In: $CYTR CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio's Expanded Phase 2 Study of Pancreatic Cancer Treatment

Third-Line Cohort Added to Phase 2 Pancreatic Cancer Trial for Combination Immunotherapy That Includes Aldoxorubicin, ImmunityBio’s N-803 and NantKwest’s PD-L1 t-haNK Three Trial Sites in California and South Dakota Will Initially Enroll 298 Patients Across...

Find out more CYTR - CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio's Expanded Phase 2 Study of Pancreatic Cancer Treatment